{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:54:40Z","timestamp":1788216880601,"version":"build-2803163510"},"reference-count":141,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clinthera.2017.11.002","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T07:15:26Z","timestamp":1512544526000},"page":"2420-2436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Integrins: Integrating the Biology and Therapy of Cell\u2013cell Interactions"],"prefix":"10.1016","volume":"39","author":[{"given":"Franco","family":"Pandolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Franza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mandolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aftab","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Kurnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.11.002_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ceb.2012.09.002","article-title":"Cell-cell adhesion and extracellular matrix: diversity counts","volume":"24","author":"Heisenberg","year":"2012","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","article-title":"The integrins","volume":"8","author":"Takada","year":"2007","journal-title":"Genome Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0955-0674(00)00132-0","article-title":"T-lymphocyte-epithelial-cell interactions: integrin alpha(E)(CD103)beta(7), LEEP-CAM and chemokines","volume":"12","author":"Agace","year":"2000","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib4","doi-asserted-by":"crossref","first-page":"696812","DOI":"10.1155\/2014\/696812","article-title":"Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin","volume":"2014","author":"Cianci","year":"2014","journal-title":"Journal of immunology research"},{"key":"10.1016\/j.clinthera.2017.11.002_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12026-009-8101-1","article-title":"Leukocyte integrins and their ligand interactions","volume":"45","author":"Hyun","year":"2009","journal-title":"Immunol Res"},{"key":"10.1016\/j.clinthera.2017.11.002_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of beta7 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.clinthera.2016.02.028","article-title":"Key role of DAMP in inflammation, cancer, and tissue repair","volume":"38","author":"Pandolfi","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.11.002_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cytogfr.2013.05.004","article-title":"The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response","volume":"24","author":"Pagliari","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.clinthera.2017.11.002_bib9","first-page":"141","article-title":"IL-32: a newly-discovered proinflammatory cytokine","volume":"23","author":"Felaco","year":"2009","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2017.11.002_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0955-0674(02)00367-8","article-title":"Selectins: lectins that initiate cell adhesion under flow","volume":"14","author":"McEver","year":"2002","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib11","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ni1275","article-title":"Immune cell migration in inflammation: present and future therapeutic targets","volume":"6","author":"Luster","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/40166","article-title":"Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells","volume":"389","author":"Fuhlbrigge","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.11.002_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2011-04-292128","article-title":"Reconstruction of integrin activation","volume":"119","author":"Ye","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2017.11.002_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ceb.2012.08.011","article-title":"Inside-out, outside-in, and inside-outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction","volume":"24","author":"Shen","year":"2012","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ceb.2012.05.004","article-title":"Opening the floodgates: proteomics and the integrin adhesome","volume":"24","author":"Geiger","year":"2012","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib16","first-page":"239","article-title":"Tissue infiltrating lymphocytes: the role of cytokines in their growth and differentiation","volume":"24","author":"Cianci","year":"2010","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2017.11.002_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ceb.2012.08.004","article-title":"Regulation of adhesion site dynamics by integrin traffic","volume":"24","author":"Valdembri","year":"2012","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1084\/jem.177.1.57","article-title":"Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma","volume":"177","author":"Baron","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2017.11.002_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1189\/jlb.0804460","article-title":"Targeting leukocyte integrins in human diseases","volume":"77","author":"Yonekawa","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.11.008","article-title":"Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease","volume":"147","author":"Mitroulis","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.11.002_bib22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.158.5.2099","article-title":"Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells","volume":"158","author":"Picarella","year":"1997","journal-title":"Journal of immunology (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.clinthera.2017.11.002_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2017.11.002_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","article-title":"Integrins as therapeutic targets","volume":"33","author":"Goodman","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2017.11.002_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","article-title":"A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin","volume":"16","author":"Gordon","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.11.002_bib27","first-page":"Cd006097","article-title":"Natalizumab for induction of remission in Crohn's disease","author":"Macdonald","year":"2006","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1016\/j.clinthera.2017.11.002_bib28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"key":"10.1016\/j.clinthera.2017.11.002_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib30","first-page":"1295","article-title":"Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease","volume":"11","author":"Tilg","year":"2010","journal-title":"Current opinion in investigational drugs (London, England: 2000)"},{"key":"10.1016\/j.clinthera.2017.11.002_bib31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1756283X16643242","article-title":"Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis","volume":"9","author":"Sofia","year":"2016","journal-title":"Therapeutic advances in gastroenterology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/imt.12.85","article-title":"Vedolizumab for the treatment of ulcerative colitis and Crohn's disease","volume":"4","author":"McLean","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clinthera.2017.11.002_bib34","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1097\/MD.0000000000000556","article-title":"Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.clinthera.2017.11.002_bib35","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"key":"10.1016\/j.clinthera.2017.11.002_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/2040622315586970","article-title":"Vedolizumab: an alpha4beta7 integrin antagonist for ulcerative colitis and Crohn's disease","volume":"6","author":"Cherry","year":"2015","journal-title":"Therapeutic advances in chronic disease"},{"key":"10.1016\/j.clinthera.2017.11.002_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MOG.0b013e3283622914","article-title":"Moving towards disease modification in inflammatory bowel disease therapy","volume":"29","author":"Allen","year":"2013","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007571","article-title":"Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis","author":"Behm","year":"2009","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1016\/j.clinthera.2017.11.002_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bph.12134","article-title":"Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells","volume":"169","author":"Pan","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/13543784.2016.1148137","article-title":"Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease","volume":"25","author":"McLean","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2017.11.002_bib41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cgh.2006.11.001","article-title":"A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease","volume":"5","author":"Yacyshyn","year":"2007","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"key":"10.1016\/j.clinthera.2017.11.002_bib43","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2017.11.002_bib44","doi-asserted-by":"crossref","first-page":"e00098","DOI":"10.1002\/prp2.98","article-title":"Prediction of clinical pharmacokinetics of AMG 181, a human anti-alpha 4 beta 7 monoclonal antibody for treating inflammatory bowel diseases","volume":"3","author":"Li","year":"2015","journal-title":"Pharmacology research & perspectives"},{"key":"10.1016\/j.clinthera.2017.11.002_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11938-016-0099-6","article-title":"Management of inflammatory bowel disease in the elderly","volume":"14","author":"John","year":"2016","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib46","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/MIB.0000000000000865","article-title":"Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease","volume":"22","author":"Singh","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinthera.2017.11.002_bib47","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1476-5381.2011.01205.x","article-title":"A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes","volume":"162","author":"Stefanich","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5009\/gnl14226","article-title":"Current and emerging biologics for ulcerative colitis","volume":"9","author":"Park","year":"2015","journal-title":"Gut and liver"},{"key":"10.1016\/j.clinthera.2017.11.002_bib49","first-page":"243","article-title":"Advances in the development of new biologics in inflammatory bowel disease","volume":"29","author":"Ungar","year":"2016","journal-title":"Annals of gastroenterology: quarterly publication of the Hellenic Society of Gastroenterology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib50","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and safety of natalizumab and vedolizumab for the management of Crohn's disease: a systematic review and meta-analysis","volume":"21","author":"Chandar","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinthera.2017.11.002_bib51","first-page":"1932","article-title":"Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis","volume":"25","author":"Elewaut","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1721727X16636889","article-title":"The effect of infliximab on bone healing in osteoporotic rats","volume":"14","author":"Durmuslar","year":"2016","journal-title":"European Journal of Inflammation"},{"key":"10.1016\/j.clinthera.2017.11.002_bib53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40273-016-0436-6","article-title":"Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy: an evidence review group perspective of a NICE single technology appraisal","volume":"34","author":"Rafia","year":"2016","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2017.11.002_bib54","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1136\/gutjnl-2016-312439","article-title":"Blockade of \u03b1E\u03b27 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo","volume":"66","author":"Zundler","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2017.11.002_bib55","doi-asserted-by":"crossref","first-page":"894704","DOI":"10.1155\/2011\/894704","article-title":"The immune response to tumors as a tool toward immunotherapy","volume":"2011","author":"Pandolfi","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib56","first-page":"255","article-title":"Nonhuman primate models in AIDS research","volume":"8","author":"Evans","year":"2013","journal-title":"Current opinion in HIV and AIDS"},{"key":"10.1016\/j.clinthera.2017.11.002_bib57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1126\/science.280.5362.427","article-title":"Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection","volume":"280","author":"Veazey","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.11.002_bib58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1084\/jem.20040874","article-title":"CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract","volume":"200","author":"Brenchley","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib59","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.20041196","article-title":"Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract","volume":"200","author":"Mehandru","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib60","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4049\/jimmunol.152.7.3282","article-title":"Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo","volume":"152","author":"Hamann","year":"1994","journal-title":"Journal of immunology (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.clinthera.2017.11.002_bib61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2017.11.002_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-immunol-020711-075001","article-title":"Microbial translocation across the GI tract","volume":"30","author":"Brenchley","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/mi.2009.90","article-title":"Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection","volume":"2","author":"Kader","year":"2009","journal-title":"Mucosal immunology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib64","doi-asserted-by":"crossref","first-page":"20877","DOI":"10.1073\/pnas.0911796106","article-title":"The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1","volume":"106","author":"Cicala","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.clinthera.2017.11.002_bib65","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ni1566","article-title":"HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells","volume":"9","author":"Arthos","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.aag1276","article-title":"Sustained virologic control in SIV+ macaques after antiretroviral and alpha4beta7 antibody therapy","volume":"354","author":"Byrareddy","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2017.11.002_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nmeth.3320","article-title":"Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques","volume":"12","author":"Santangelo","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.clinthera.2017.11.002_bib68","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2017.11.002_bib69","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI26989","article-title":"Structure and function of the platelet integrin alphaIIbbeta3","volume":"115","author":"Bennett","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2017.11.002_bib70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: biological basis, clinical use and new drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2017.11.002_bib71","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.ATV.17.3.528","article-title":"7E3 monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1","volume":"17","author":"Simon","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib72","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ahj.2006.04.035","article-title":"Benefit of bolus-only platelet glycoprotein IIb\/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial","volume":"152","author":"Marmur","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2017.11.002_bib73","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1083\/jcb.200208043","article-title":"Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2","volume":"160","author":"Inoue","year":"2003","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib74","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1160\/TH09-06-0358","article-title":"A small-molecule inhibitor of integrin alpha2 beta1 introduces a new strategy for antithrombotic therapy","volume":"103","author":"Nissinen","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2017.11.002_bib75","doi-asserted-by":"crossref","first-page":"714218","DOI":"10.1155\/2014\/714218","article-title":"Advances in medical revascularisation treatments in acute ischemic stroke","volume":"2014","author":"Asadi","year":"2014","journal-title":"Thrombosis"},{"key":"10.1016\/j.clinthera.2017.11.002_bib76","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/0394632015608247","article-title":"Endothelial immunomediated reactivity in acute cardiac ischaemia: role of endothelin 1, interleukin 8 and NT-proBNP in patients affected by unstable angina pectoris","volume":"29","author":"Caroselli","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00129784-200303050-00011","article-title":"Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization","volume":"3","author":"Ibbotson","year":"2003","journal-title":"American journal of cardiovascular drugs : drugs, devices, and other interventions"},{"key":"10.1016\/j.clinthera.2017.11.002_bib78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/STROKEAHA.106.476648","article-title":"Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)","volume":"39","author":"Adams","year":"2008","journal-title":"Stroke"},{"issue":"Suppl L","key":"10.1016\/j.clinthera.2017.11.002_bib79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/eurheartj\/16.suppl_L.43","article-title":"An overview of the results of the EPIC trial","volume":"16","author":"Califf","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2017.11.002_bib80","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3949\/ccjm.65.5.267","article-title":"The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve long-term outcome with abciximab GP IIb\/IIIa blockade","volume":"65","author":"Roe","year":"1998","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib81","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study","volume":"349","year":"1997","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2017.11.002_bib82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)85010-1","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","year":"1998","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2017.11.002_bib83","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib84","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","article-title":"Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa","volume":"268","author":"Scarborough","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2017.11.002_bib85","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0030-1267856","article-title":"Review of currently available GP IIb\/IIIa inhibitors and their role in peripheral vascular interventions","volume":"27","author":"Stangl","year":"2010","journal-title":"Seminars in interventional radiology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib86","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II","volume":"349","year":"1997","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2017.11.002_bib87","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0002-8703(00)90089-9","article-title":"Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide. The PURSUIT trial investigators","volume":"139","author":"Hasdai","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2017.11.002_bib88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCINTERVENTIONS.108.809285","article-title":"Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb\/IIIa blockade: findings of the ESPRIT trial","volume":"2","author":"Tcheng","year":"2009","journal-title":"Circulation. Cardiovascular interventions"},{"key":"10.1016\/j.clinthera.2017.11.002_bib89","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1212\/NXI.0000000000000212","article-title":"CNS accumulation of regulatory B cells is VLA-4-dependent","volume":"3","author":"Lehmann-Horn","year":"2016","journal-title":"Neurology neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.clinthera.2017.11.002_bib90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1474-4422(11)70299-X","article-title":"Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"11","author":"Miller","year":"2012","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/intimm\/dxu096","article-title":"Therapeutic uses of anti-alpha4-integrin (anti-VLA-4) antibodies in multiple sclerosis","volume":"27","author":"Schwab","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clim.2016.08.003","article-title":"Leukocyte adhesion molecule dynamics after natalizumab withdrawal in multiple sclerosis","volume":"171","author":"Cobo-Calvo","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib93","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib94","doi-asserted-by":"crossref","first-page":"357101","DOI":"10.1155\/2012\/357101","article-title":"Anti-integrin therapy for multiple sclerosis","volume":"2012","author":"Kawamoto","year":"2012","journal-title":"Autoimmune diseases"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2017.11.002_bib95","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1053\/j.seminhematol.2016.04.016","article-title":"Immunological treatment of multiple sclerosis","volume":"53","author":"Diebold","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib96","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/ene.12992","article-title":"Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years","volume":"23","author":"Zivadinov","year":"2016","journal-title":"European journal of neurology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib97","doi-asserted-by":"crossref","first-page":"e0160277","DOI":"10.1371\/journal.pone.0160277","article-title":"Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation","volume":"11","author":"Iannetta","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2017.11.002_bib98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib99","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2147\/TCRM.S5218","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"5","author":"Brown","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2017.11.002_bib100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2014.03.007","article-title":"Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab","volume":"340","author":"Valenzuela","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinthera.2017.11.002_bib101","doi-asserted-by":"crossref","first-page":"ofw038","DOI":"10.1093\/ofid\/ofw038","article-title":"Acute cryptococcal immune reconstitution inflammatory syndrome in a patient on natalizumab","volume":"3","author":"Gundacker","year":"2016","journal-title":"Open forum infectious diseases"},{"key":"10.1016\/j.clinthera.2017.11.002_bib102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jnr.20522","article-title":"Decreased FOXP3 levels in multiple sclerosis patients","volume":"81","author":"Huan","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.clinthera.2017.11.002_bib103","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4049\/jimmunol.1700495","article-title":"Not just an adhesion molecule: LFA-1 contact tunes the T lymphocyte program","volume":"199","author":"Verma","year":"2017","journal-title":"Journal of immunology (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.clinthera.2017.11.002_bib104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1083\/jcb.107.1.321","article-title":"Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells","volume":"107","author":"Dustin","year":"1988","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib105","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/TP.0000000000000805","article-title":"Impact of leukocyte function-associated antigen-1 blockade on endogenous allospecific T cells to multiple minor histocompatibility antigen mismatched cardiac allograft","volume":"99","author":"Kwun","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2017.11.002_bib106","doi-asserted-by":"crossref","first-page":"e30308","DOI":"10.1371\/journal.pone.0030308","article-title":"Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs","volume":"7","author":"Johnson-Huang","year":"2012","journal-title":"PloS one"},{"key":"10.1016\/j.clinthera.2017.11.002_bib107","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib108","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2013.00222","article-title":"Tumor targeting via integrin ligands","volume":"3","author":"Marelli","year":"2013","journal-title":"Frontiers in oncology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ddr.20265","article-title":"Integrin alpha(v)beta(3)-targeted cancer therapy","volume":"69","author":"Liu","year":"2008","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.clinthera.2017.11.002_bib110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/187152006778226530","article-title":"Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism","volume":"6","author":"Cai","year":"2006","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.clinthera.2017.11.002_bib111","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1155\/2013\/135164","article-title":"Integrin signaling as a cancer drug target","volume":"2013","author":"Danen","year":"2013","journal-title":"ISRN Cell Biology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib112","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","article-title":"A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2017.11.002_bib113","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bjc.2011.183","article-title":"A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma","volume":"105","author":"O'Day","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2017.11.002_bib114","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00280-014-2576-8","article-title":"A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors","volume":"74","author":"Mateo","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib115","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-06-2779","article-title":"Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors","volume":"13","author":"Mullamitha","year":"2007","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.clinthera.2017.11.002_bib116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinthera.2017.11.002_bib117","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1535-7163.MCT-06-0100","article-title":"A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo","volume":"5","author":"Khalili","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clinthera.2017.11.002_bib118","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/bjc.2016.312","article-title":"The complexity of integrins in cancer and new scopes for therapeutic targeting","volume":"115","author":"Hamidi","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2017.11.002_bib119","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2013-06-511527","article-title":"Reciprocal leukemia-stroma VCAM-1\/VLA-4-dependent activation of NF-kappaB mediates chemoresistance","volume":"123","author":"Jacamo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2017.11.002_bib120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fonc.2014.00099","article-title":"Role of integrin alpha4 in drug resistance of leukemia","volume":"4","author":"Shishido","year":"2014","journal-title":"Frontiers in oncology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib121","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","article-title":"A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer","volume":"121","author":"Bell-McGuinn","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib122","first-page":"255","article-title":"Pathogenesis of thrombosis. Hematology. American Society of Hematology","author":"Furie","year":"2009","journal-title":"Education Program"},{"key":"10.1016\/j.clinthera.2017.11.002_bib123","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0735-1097(00)00919-0","article-title":"Evidence of platelet activation during treatment with a GPIIb\/IIIa antagonist in patients presenting with acute coronary syndromes","volume":"36","author":"Cox","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib124","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd1174","article-title":"Therapeutic antagonists and conformational regulation of integrin function","volume":"2","author":"Shimaoka","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2017.11.002_bib125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm.1941","article-title":"Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors","volume":"15","author":"Reynolds","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2017.11.002_bib126","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd3266","article-title":"Integrins as therapeutic targets: lessons and opportunities","volume":"9","author":"Cox","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2017.11.002_bib127","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib128","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1124\/jpet.102.047704","article-title":"A small molecule alpha4beta1\/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence","volume":"306","author":"Egger","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2017.11.002_bib129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0394632015623794","article-title":"Analysis of changes in expression of IL-4\/IL-13\/STAT6 pathway and correlation with the selected clinical parameters in patients with atopic asthma","volume":"29","author":"Antczak","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib130","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1365-2222.2005.02296.x","article-title":"Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma","volume":"35","author":"Diamant","year":"2005","journal-title":"Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib131","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00196101","article-title":"Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors","volume":"16","author":"Metzger","year":"1995","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib132","first-page":"585","article-title":"Pneumomediastinum, subcutaneous emphysema and pneumorrhachis in asthmatic children","volume":"30","author":"Colavita","year":"2016","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2017.11.002_bib133","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1398-9995.2006.01146.x","article-title":"The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma","volume":"61","author":"Ravensberg","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2017.11.002_bib134","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/0394632015582316","article-title":"From modeling to remodeling of upper airways: centrality of hyaluronan (hyaluronic acid)","volume":"29","author":"Castelnuovo","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2017.11.002_bib135","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/jc.2004-2126","article-title":"Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"90","author":"Murphy","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.11.002_bib136","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/annonc\/mds505","volume":"24","author":"Heidenreich","year":"2013","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.clinthera.2017.11.002_bib137","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/sj.bjc.6603171","article-title":"Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours","volume":"94","author":"Cianfrocca","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2017.11.002_bib138","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2017.11.002_bib139","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/2048872612474922","article-title":"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS","volume":"2","author":"Hess","year":"2013","journal-title":"European heart journal. Acute cardiovascular care"},{"key":"10.1016\/j.clinthera.2017.11.002_bib140","first-page":"1356","article-title":"Clinical effects of treatment with tirofiban on patients with high-risk NSTE-ACS after PCI","volume":"20","author":"Wei","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2017.11.002_bib141","doi-asserted-by":"crossref","first-page":"e0113483","DOI":"10.1371\/journal.pone.0113483","article-title":"A pilot study of omalizumab in eosinophilic esophagitis","volume":"10","author":"Loizou","year":"2015","journal-title":"PLoS ONE"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:06:53Z","timestamp":1693332413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817310640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":141,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0149291817310640"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.11.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrins: Integrating the Biology and Therapy of Cell\u2013cell Interactions","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}